HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $42 to $35.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A
Cocrystal Pharma Inc (NASDAQ:COCP) announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the…
Cocrystal Pharma Q3 EPS $(0.70) Down From $(0.48) YoY
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.70) per share. This is a 45.83 percent decrease over losses of $(0.48) per share from the same period last year.
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
Cocrystal Pharma Has Been Granted European Patent Number EP3866778 Titled “Combinations Of Inhibitors Of Influenza Virus Replication”
About this file - European Patent Register (epo.org)
(2) PatentGrants on Twitter: "$COCP Cocrystal Pharma has been granted European patent number EP3866778 titled "COMBINATIONS OF INHIBITORS OF INFLUENZA VIRUS
